New insights and approaches to reduce end-organ damage in the treatment of hypertension: subsets of hypertension approach
- PMID: 1575152
- DOI: 10.1016/0002-8703(92)91042-y
New insights and approaches to reduce end-organ damage in the treatment of hypertension: subsets of hypertension approach
Abstract
Antihypertensive therapy should be directed toward reduction of all end-organ damage including congestive heart failure, left ventricular hypertrophy, coronary heart disease, myocardial infarction, cerebrovascular accident, and chronic renal failure. The Subsets of hypertension approach is based on pathophysiology, hemodynamics, risk factor reduction for end-organ damage, concomitant diseases and problems, demographics, adverse effects on quality of life, compliance, and total health care costs. This approach provides a more individualized and logical treatment of the hypertensive syndrome and addresses the metabolic and structural abnormalities that are present.
Similar articles
-
Hypertension strategies for therapeutic intervention and prevention of end-organ damage.Prim Care. 1991 Sep;18(3):713-53. Prim Care. 1991. PMID: 1946795 Review.
-
Hypertension and coronary heart disease risk factor management.Clin Auton Res. 1993 Dec;3(6):357-61. doi: 10.1007/BF01829453. Clin Auton Res. 1993. PMID: 8193521
-
Retrospective and prospective research on hypertension-related end-organ damage.J Cardiovasc Pharmacol. 1994;24 Suppl A:S1-5. J Cardiovasc Pharmacol. 1994. PMID: 7603071
-
The management of hypertension and associated risk factors for the prevention of long-term cardiac complications.J Cardiovasc Pharmacol. 1993;21 Suppl 2:S2-13. doi: 10.1097/00005344-199321002-00002. J Cardiovasc Pharmacol. 1993. PMID: 7692147 Review.
-
New insights and new approaches for the treatment of essential hypertension: selection of therapy based on coronary heart disease risk factor analysis, hemodynamic profiles, quality of life, and subsets of hypertension.Am Heart J. 1989 Apr;117(4):911-51. doi: 10.1016/0002-8703(89)90631-5. Am Heart J. 1989. PMID: 2648781 Review.
Cited by
-
The impact of metabolic syndrome on metabolic, pro-inflammatory and prothrombotic markers according to the presence of high blood pressure criterion.Clinics (Sao Paulo). 2013 Dec;68(12):1495-501. doi: 10.6061/clinics/2013(12)04. Clinics (Sao Paulo). 2013. PMID: 24473506 Free PMC article.
-
[Hypertension and cardiac failure].Internist (Berl). 2007 Sep;48(9):909-20. doi: 10.1007/s00108-007-1913-y. Internist (Berl). 2007. PMID: 17713747 Review. German.
-
[Atenolol/nifedipine combination: efficacy and tolerability of low dose synergistic bitherapy in the treatment of arterial hypertension].Drugs. 1998;56 Suppl 2:31-43. doi: 10.2165/00003495-199856002-00004. Drugs. 1998. PMID: 9813740 Review. French.
-
[Cardiovascular end organ impairment due to hypertension].Internist (Berl). 2005 May;46(5):496-508. doi: 10.1007/s00108-005-1394-9. Internist (Berl). 2005. PMID: 15806411 Review. German.
-
Sympathoadrenergic overactivity and lipid metabolism.Cardiovasc Drugs Ther. 1996 Jun;10 Suppl 1:223-30. doi: 10.1007/BF00120491. Cardiovasc Drugs Ther. 1996. PMID: 8827944
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical